Business
Tiziana is Pleased to Retain Dr. Napoleone Ferrara to Serve on Its Scientific Advisory Board for an Additional Three-Year Term
- Dr. Ferrara is the discoverer of Avastin® and Lucentis®, multi-billion dollars antibody drugs from Genentech - A member of National Academy of Sciences and
About this update from Tiziana Life Sciences Ltd
[{"type":"text","content":"- Dr. Ferrara is the discoverer of Avastin® and Lucentis®, multi-billion dollars antibody drugs from Genentech - A member of National Academy of Sciences and recipient of several prestigious awards, including the Lasker award. NEW YORK and LONDON, Aug. 20, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA; AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, announces that Dr. Napoleone Ferrara, MD, Professor at the University of California San Diego Medical Center, has agreed to serve on its scientific advisory board (SAB) for an additional three year term. Dr. Ferrara brings 30 plus years of experience in clinical development of monoclonal antibodies (mAbs), which has been very useful in the formulation and clinical development of Foralumab, a fully human anti-CD3 mAb, as well as other immunotherapy projects. Dr. Ferrara is a member of The National Academy of Sciences and has received numerous prestigious awards, including the Lasker Award and the Breakthrough Prize in Life Sciences. His research on understanding the role of angiogenesis and vascular endothelial growth factor (VEGF) in cancer development, led to the development and approval of humanized anti-VEGF mAbs (Bevacizumab; Avastin®) for cancer treatment. Dr. Ferrara also discovered that VEGF is a key mediator of angiogenesis associated with intraocular neovascular syndromes. This pioneering research led to the clinical development of a humanized anti-VEGF Fab (Ranibizumab, Lucentis®), which has also been approved as a therapy for neovascular age-related macular degeneration (AMD), retinal vein occlusion and diabetic macular edema. Ranibizumab and other anti-VEGF agents have had a dramatic impact on the development of therapies for these blinding disorders. Dr. Napoleone Ferrara stated: “I am excited to continue to serve on Tiziana’s SAB as I believe that the immunotherapy pipeline of the company is highly innovative and conceptually very logical. The approaches to administer mAbs by oral and nasal routes to stimulate mucosal immune system to induce disease modifying benefits are like human physiological defense systems. Thus, these alternative routes of administration have potential to transform immunotherapies.” “We are delighted to continue our relations...